activator of HSP90 ATPase homolog 2, pseudogeneGenealiases: []
Q-omics provides the consensus-scored AHSA2P profile across patient tissues and cancer cell-line models. AHSA2P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AHSA2P is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, AHSA2P RNA expression shows 19,576 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where AHSA2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AHSA2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AHSA2P survival associations across molecular data types. AHSA2P RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AHSA2P RNA expression–survival associations across cancer types. High AHSA2P expression shows unfavorable associations in KIRC, UVM, ACC, COAD and MESO, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AHSA2P RNA expression.
This table summarizes AHSA2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AHSA2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AHSA2P shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, COAD, HNSC and CHOL. The KIRC box plot shows higher AHSA2P RNA expression in tumor versus normal tissue (log2 FC = +0.969, t-test p < 0.001).
This table shows molecular features associated with AHSA2P in patient tissues and cancer cell lines. In patient samples, AHSA2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AHSA2P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and NCI60_ALL.
